

Journal name: Targeted Oncology

Article title: Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines

Author names: Maria Pinkerneil¹, Michèle J Hoffmann¹, Hella Kohlhof², Wolfgang A Schulz¹, Günter Niegisch^{1§}

¹Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany

²4SC AG, Martinsried, Germany

E-Mail corresponding author: Guenter.Niegisch@med.uni-duesseldorf.de

Supplementary Tab S1. Bladder cancer cell lines and control cells used in this study and their origins. STR profiling for UCCs and control cells was recently performed (Modified from Williams et al., 2005 (1) and Pinkerneil et al., 2016 (2); DSMZ – Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany).

Cell line	Fingerprint	Source	Reference
RT-112	Dec 2013	DSMZ (ACC 418)	(3, 4)
SW-1710	Dec 2013	DSMZ (ACC 426)	(5)
5637	Dec 2013	DSMZ (ACC 35)	(6)
639-V	Dec 2013	Fogh J, New York, USA	(7)
T-24	Dec 2013	Fogh J, New York, USA	(6, 8)
UM-UC-3	Dec 2013	Grossman HB, Houston, USA	(9)
VM-CUB1	Dec 2013	DSMZ (ACC 400)	(6, 10)
TERT-NHUC	Dec 2013	Knowles MA, Leeds, UK	(11, 12)
HBLAK	June 2015	CELLnTEC, Bern, Switzerland	
HEK-293	June 2015	Kolb-Bachofen V, Duesseldorf, Germany	(13)

Supplementary Tab S2. Primer assays for RT-PCR. QuantiTect primer assays and self-designed TBP-primer used for quantitative RT-PCR and determination of expression levels of class I HDACs HDAC1, HDAC2, HDAC3 and HDAC8 (Modified from Pinkerneil et al., 2016 (2)).

Gene name	Size (bp)	Cat. No./Sequence 5'-3'	T_{Annealing} (°C)
HDAC1	140	QT00015239	55
HDAC2	127	QT00001890	55
HDAC3	100	QT00093730	55
HDAC8	124	QT00049630	55
TBP	119	Fwd. ACAACAGCCTGCCACCTTA Rev. GAATAGGCTGTGGGTCAGT	55

Supplementary Tab S3. Antibodies used for western blot analyses. Antibodies for western blotting of whole cell lysates and histone extracts, including specifications and dilutions (Modified from Pinkerney et al., 2016 (2)).

Target	Size (kDa)	Dilution	Cat. No.	Source
P21 Sx118	21	1:1,000	556430	BD Biosciences
Cyclin A H-432	54	1:1,000	sc-751	Santa Cruz Biotechnology
Cyclin B1 H-433	60	1:1,000	sc-752	Santa Cruz Biotechnology
Cyclin D1 H-295	37	1:1,000	sc-753	Santa Cruz Biotechnology
Cyclin E HE-12	53	1:500	sc-247	Santa Cruz Biotechnology
Cleaved PARP Asp214	89	1:1,000	9541	Cell Signaling Technology
Cleaved caspase-3	17	1:1,000	9664	Cell Signaling Technology
Acetylated α-Tubulin	55	1:15,000	T-7451	Sigma Aldrich
GAPDH	36	1:10,000	ab8245	Abcam
Acetylated Histone H3	17	1:2,000	39139	Active Motif
Acetylated Histone H4	8	1:1,000	39243	Active Motif
Total histone H3	17	1:1,000	3638	Cell Signaling Technology
HRP-conjugated goat-anti-mouse	---	1:5,000 - 1:100,000	sc-2005	Santa Cruz Biotechnology
HRP-conjugated goat-anti-rabbit	---	1:5,000 - 1:100,000	Sc-2004	Santa Cruz Biotechnology

1. Williams SV, Adams J, Coulter J, Summersgill BM, Shipley J, Knowles MA. Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro. *Genes, chromosomes & cancer*. 2005;43:315-28.
2. Pinkerneil M, Hoffmann MJ, Deenen R, Köhrer K, Arent T, Schulz WA, et al. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms. *Molecular cancer therapeutics*. 2016;15:299-312.
3. Masters JR, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, et al. Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. *Cancer research*. 1986;46:3630-6.
4. Marshall CJ, Franks LM, Carbonell AW. Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. *Journal of the National Cancer Institute*. 1977;58:1743-51.
5. Kyriazis AA, Kyriazis AP, McCombs WB, 3rd, Peterson WD, Jr. Morphological, biological, and biochemical characteristics of human bladder transitional cell carcinomas grown in tissue culture and in nude mice. *Cancer research*. 1984;44:3997-4005.
6. Williams RD. Human urologic cancer cell lines. *Investigative urology*. 1980;17:359-63.
7. Elliott AY, Bronson DL, Stein N, Fraley EE. In vitro cultivation of epithelial cells derived from tumors of the human urinary tract. *Cancer research*. 1976;36:365-9.
8. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. *International journal of cancer Journal international du cancer*. 1973;11:765-73.
9. Grossman HB, Wedemeyer G, Ren L, Wilson GN, Cox B. Improved growth of human urothelial carcinoma cell cultures. *The Journal of urology*. 1986;136:953-9.
10. Grimm MO, Jurgens B, Schulz WA, Decken K, Makri D, Schmitz-Drager BJ. Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. *Urological research*. 1995;23:293-300.
11. Chapman EJ, Williams SV, Platt FM, Hurst CD, Chambers P, Roberts P, et al. Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase-immortalized urothelial cells (TERT-NHUC). *Genes, chromosomes & cancer*. 2009;48:694-710.
12. Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS, Knowles MA. Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. *Oncogene*. 2006;25:5037-45.
13. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *The Journal of general virology*. 1977;36:59-74.